3-Methyl-2-phenyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-Methyl-2-phenyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridin-4-amine
• 英文别名: 3-methyl-2-phenyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-b]pyridin-4-amine
• 化学式: C₁₈H₁₈N₂S
• 分子量: 294.4
• InChiKey: JIFKVRPMGDWZAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
  申请人：Bush Erik

  公开号：US20050288331A1

  公开（公告）日：2005-12-29

  The present invention provides certain compounds, pharmaceutical formulations thereof, and methods for the treatment of conditions mediated by 5-HT2 receptors. These compounds provide for modulation of the signals mediated by 5-HT2 receptors, specifically those receptors in the cardiovascular system. Thus, these compounds may be used alone or in conjunction with other drugs to treat cardiovascular diseases such as, but not limited to, muscle atrophy, cardiac hypertrophy, heart failure, and primary pulmonary hypertension.

  本发明提供了某些化合物、其药物制剂以及治疗由 5-HT2 受体介导的疾病的方法。这些化合物可调节由 5-HT2 受体介导的信号，特别是心血管系统中的受体。因此，这些化合物可单独使用或与其他药物联合使用，以治疗心血管疾病，如但不限于肌肉萎缩、心脏肥大、心力衰竭和原发性肺动脉高压。
• Modulation of 5-HT2 receptors as a treatment for cardiovascular diseases
  申请人：Bush Erik

  公开号：US20050265999A1

  公开（公告）日：2005-12-01

  The present invention provides for methods of treating and preventing muscle atrophy, cardiac hypertrophy, heart failure and/or primary pulmonary hypertension linked to a family of serotonin receptors called 5-HT2 receptors. The present invention further demonstrates that modulators of 5-HT2 receptors can inhibit or treat muscle atrophy, heart failure, cardiac hypertrophy, and/or primary pulmonary hypertension.

  本发明提供了治疗和预防肌肉萎缩、心脏肥大、心力衰竭和/或原发性肺动脉高压的方法，这些疾病与称为 5-HT2 受体的血清素受体家族有关。本发明进一步证明，5-HT2 受体的调节剂可以抑制或治疗肌肉萎缩、心力衰竭、心脏肥大和/或原发性肺动脉高压。
• 5-HT2 RECEPTORS MODULATORS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR AND MUSCLE DISEASES
  申请人：MYOGEN, INC.

  公开号：EP1701943A1

  公开（公告）日：2006-09-20
• MODULATION OF 5-HT2 RECEPTORS AS A TREATMENT FOR CARDIOVASCULAR DISEASES
  申请人：Board of Regents, The University of Texas System

  公开号：EP1696895A1

  公开（公告）日：2006-09-06
• US7638519B2
  申请人：——

  公开号：US7638519B2

  公开（公告）日：2009-12-29